ScripThe market for BCMA-directed therapies to treat multiple myeloma just got a little more crowded with the US Food and Drug Administration giving the green light to Regeneron Pharmaceuticals’ Lynozyfic
ScripUnicycive has already identified a new manufacturing vendor, the company said, which could help it quickly resolve a complete response letter issued by the US Food and Drug Administration for oxylanth
ScripWho: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C
ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti